Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
NASH - Nonalcoholic Steatohepatitis
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed…
- Trial name
- NCT03551522
- Testing
- Seladelpar
- Where
- 14 sites in United States
- Volunteers
- 181 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Fatty Liver Disease, Obesity
Optimal Exercise Frequency to Reduce Liver Fat in Centrally Obese Adults With Non-Alcoholic Fatty Liver Disease
This study aims to examine the comparative effectiveness of different exercise frequencies (once-a-week vs. thrice-a-week) for reducing liver fat in centrally obese adults with non-alcoholic fatty liver disease (NAFLD), with…
- Trial name
- NCT05741957
- Testing
- Once-a-week Exercise, Thrice-a-week Exercise, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- The University of Hong Kong
Type 2 Diabetes (T2DM), Metabolic Dysfunction-Associated Steatotic Liver Disease
Cardiovascular Risk in T2DM With MAFLD: A Cohort Study
This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes…
- Trial name
- NCT07706010
- Where
- China
- Volunteers
- 7,000 people
- Sponsor
- The Affiliated Hospital of Hangzhou Normal University
NAFLD - Nonalcoholic Fatty Liver Disease
Studying Non Alcoholic Fatty Liver Disease and Liver Fibrosis Among Systemic Lupus Erythematosus Patients at Assiut University Hospital
Aim of the study :- 1. to estimate prevalence of non alcoholic fatty liver disease and liver fibrosis among Systemic lupus erythematosus patients 2.
- Trial name
- NAFLD and SLE (NCT06601361)
- Testing
- Fibroscan
- Volunteers
- 112 people
- Sponsor
- Assiut University
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver Disease - Intermittent Calorie Restriction (FLICR) Study
Several diets have been proposed to reduce liver steatosis in patients with nonalcoholic fatty liver disease (NAFLD), and various effects on liver steatosis have been observed.
- Trial name
- NCT05309642
- Testing
- Intermittent calorie restriction, Standard of care
- Where
- South Korea
- Volunteers
- 72 people
- Sponsor
- Ewha Womans University Mokdong Hospital
Hepatic Cirrhosis, Nonalcoholic Steatohepatitis
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
The study was conducted to describe and compare the plasma pharmacokinetics of NRL972 administered after a standard meal and while fasted in patients with hepatic cirrhosis (Child-Turcotte-Pugh [CTP] class A-C), NASH, young and…
- Trial name
- NCT00856869
- Testing
- NRL972
- Where
- Bulgaria
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Norgine
NAFLD, IBS
Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD
The study in question is an interventional study with nutritional intervention. the aim of the study is to evaluate whether a diet enriched with tomatoes can have favorable effects on: specific aspects associated with NAFLD, such…
- Trial name
- NCT06389851
- Testing
- Experimental: Case Group - Tomato-free diet, Experimental: Case group - Diet enriched with tomatoes
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Fatty Liver Disease
Effect of Sodium Glucose Cotransporter Inhibitors Fatty Liver Disease Patients Fatigue Assessment
Non-alcoholic fatty liver disease (NAFLD) has become a major health problem worldwide with an increasing prevalence ranging from 13% in Africa to 42% in South-East Asia.
- Trial name
- Fatty liver (NCT05694923)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Egypt
- Volunteers
- 55 people
- Sponsor
- Assiut University
NAFLD, Non-alcoholic Fatty Liver Disease
Comparing Effects of Beetroot Juice and Mediterranean Diet on Liver Enzymes and Sonography in Patients With NAFLD
The goal of this clinical trial study is to investigate comparing Effects of Beetroot juice and Mediterranean diet on Liver Enzymes and Sonographic appearance in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) The main…
- Trial name
- BJ (NCT05909631)
- Testing
- Beetroot juice, Mediterranean diet alone (MeD), Mediterranean diet with beet juice (BJ+MeD)
- Where
- Iraq
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sulaimani Polytechnic University
Nonalcoholic Fatty Liver Disease
Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study
Nonalcoholic steatohepatitis (NASH) is common, may progress to cirrhosis and is predicted to become a leading indication for liver transplantation in the near future.
- Trial name
- NCT02469272
- Testing
- Fecal Microbiota Transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Lifespan
Non-alcoholic Steatohepatitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis
This study will evaluate the efficacy, safety, and pharmacokinetics of BFKB8488A compared to placebo in participants with non-alcoholic steatohepatitis (NASH).
- Trial name
- BANFF (NCT04171765)
- Testing
- BFKB8488A
- Where
- 53 sites in United States, Belgium and 3 more
- Volunteers
- 46 people
- Sponsor
- Genentech, Inc.
Non Alcoholic Steatohepatitis
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
This study is intended to find out whether treatment with rosiglitazone improves the state of the liver and related blood markers in patients with nonalcoholic steatohepatitis (NASH).
- Trial name
- FLIRT (NCT00492700)
- Testing
- rosiglitazone
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Association pour la Recherche sur les Maladies Hépatiques Virales
Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis
A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
This is a randomized, double-blind study of MSDC-0602K or placebo in subjects with pre-T2D or T2D and evidence of NAFLD/NASH.
- Conditions
- Type2 Diabetes, NASH - Nonalcoholic Steatohepatitis, Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT03970031
- Testing
- MSDC-0602K
- Volunteers
- 1,800 people
- Sponsor
- Cirius Therapeutics, Inc.
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver
Ultrasound and Attenuation Imaging
Fatty liver disease affects almost a 3rd of the United Kingdom (UK) population. Currently, this is being investigated using a type of MRI scan that reports how fatty or not a person's liver is, with a liver fat score, but many…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non-alcoholic Steatohepatitis, Steatosis of Liver
- Trial name
- NCT06552377
- Testing
- Ultrasound Attenuation imaging measurement
- Where
- United Kingdom
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Hywel Dda Health Board
HIV Infections, Fatty Liver Disease
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
In HIV-infected people with metabolic fatty liver disease and liver fibrosis of any degree, as measured by non-invasive testing, antiretroviral treatment that includes rilpivinire for 18 months results in a slowing of progression…
- Trial name
- MAFALDA-R (NCT05898841)
- Testing
- Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day, Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day, Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- Fundacion SEIMC-GESIDA
Non-alcoholic Fatty Liver Disease, Obesity
A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver Disease
An increase in dietary protein intake has been shown to blunt the increase in intrahepatic fat induced by high fat feeding in healthy individuals.
- Trial name
- PROTOB (NCT00870077)
- Testing
- ProWHEY 94 CFM, SponserR
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- University of Lausanne
Non-alcoholic Fatty Liver Disease, Glycogen Hepatopathy
Prevalence of Metabolic Liver Diseases in Patients With Type 1 Diabetes Mellitus
Nonalcoholic fatty liver disease (NAFLD) has been extensively studied in the context of type 2 diabetes mellitus (T2D) due to its higher prevalence and its association with obesity and syndrome metabolic, a well-established risk…
- Conditions
- Non-alcoholic Fatty Liver Disease, Glycogen Hepatopathy, Type 1 Diabetes, Liver Diseases
- Trial name
- NCT05054712
- Where
- 2 sites in Spain
- Volunteers
- 250 people
- Sponsor
- Consorci Sanitari de l'Alt Penedès i Garraf
Non-Alcoholic Fatty Liver Disease
Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis
In order to determine whether rebaudioside consumption can be used as a treatment for adolescents with Non-alcoholic Fatty Liver Disease (NAFLD) by demonstrating a decrease in alanine aminotransferase (ALT) levels participants…
- Trial name
- NCT03985020
- Testing
- Stevia Intervention, Water Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Los Angeles
Liver Disease
Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients
Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are characterized by the accumulation of fat in the liver.
- Trial name
- NCT00844779
- Testing
- Bariatric surgery, cholecystectomy or benign liver tumor removal
- Where
- 2 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Strasbourg, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.